Alkylquinoline and alkylquinazoline kinase modulators

Details Alkylquinoline and alkylquinazoline kinase modulators Alkylquinoline and alkylquinazoline kinase modulators

2006-06-06

2011-12-06

Wilson, James O (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C544S122000

Reexamination Certificate

active

08071768

ABSTRACT:
The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I:wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

REFERENCES:
patent: 3517005 (1970-06-01), Cronin et al.
patent: 4001422 (1977-01-01), Danilewicz et al.
patent: 4542132 (1985-09-01), Campbell et al.
patent: 5300515 (1994-04-01), Takano et al.
patent: 5474765 (1995-12-01), Thorpe
patent: 5762918 (1998-06-01), Thorpe
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5866562 (1999-02-01), Schohe-Loop et al.
patent: 5948786 (1999-09-01), Fujiwara et al.
patent: 6169088 (2001-01-01), Matsuno et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6613772 (2003-09-01), Schindler et al.
patent: 6776796 (2004-08-01), Falotico et al.
patent: 7074801 (2006-07-01), Yoshida et al.
patent: 2002/0016625 (2002-02-01), Falotico et al.
patent: 2004/0049032 (2004-03-01), Charrier et al.
patent: 08/82717 (1998-12-01), None
patent: 1 566 379 (2005-08-01), None
patent: 2295387 (1996-05-01), None
patent: 59076082 (1984-04-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 96/32907 (1996-10-01), None
patent: WO 97/28118 (1997-08-01), None
patent: WO 97/38992 (1997-10-01), None
patent: WO 99/31086 (1999-06-01), None
patent: WO 00/13681 (2000-03-01), None
patent: WO 01/32632 (2001-05-01), None
patent: WO 02/16360 (2002-02-01), None
patent: WO 02/16362 (2002-02-01), None
patent: WO 02/32861 (2002-04-01), None
patent: WO 02/48152 (2002-06-01), None
patent: WO 02/069972 (2002-09-01), None
patent: WO 02/088107 (2002-11-01), None
patent: WO 02/092599 (2002-11-01), None
patent: WO 03/024931 (2003-03-01), None
patent: WO 03/024969 (2003-03-01), None
patent: WO 03/035009 (2003-05-01), None
patent: WO 03/037347 (2003-05-01), None
patent: WO 03/057690 (2003-07-01), None
patent: WO 03/064413 (2003-08-01), None
patent: WO 03/099771 (2003-12-01), None
patent: WO 2004/002960 (2004-01-01), None
patent: WO 2004/005281 (2004-01-01), None
patent: WO 2004/016597 (2004-02-01), None
patent: WO 2004/018419 (2004-03-01), None
patent: WO 2004/039782 (2004-05-01), None
patent: WO 2004/043389 (2004-05-01), None
patent: WO 2004/046120 (2004-06-01), None
patent: WO 2004/058727 (2004-07-01), None
patent: WO 2004/058749 (2004-07-01), None
patent: WO 2004/071460 (2004-08-01), None
patent: WO 2005/021500 (2005-03-01), None
patent: WO 2005/037825 (2005-04-01), None
patent: WO 2005/051304 (2005-06-01), None
patent: WO 2006/135646 (2006-12-01), None
patent: WO 2006/135721 (2006-12-01), None
Nomoto et al., Chemical & Pharmaceutical Bulletin (1990), 38(11), 3014-19.
Ivan, Marius G. et al. Photochemistry and Photobiology (2003), 78(4), 416-419.
Sadykov, T. et al. Khimiya Geterotsiklicheskikh Soedinenii (1985), (4), 563.
Erzhanov, K. B. et al. Zhurnal Organicheskoi Khimii (1989), 25(8), 1729-32.
Fujiwara, Norio et al. Bioorganic & Medicinal Chemistry Letters (2000), 10(12), pp. 1317-1320.
Takai, Haruki et al. Chemical & Pharmaceutical Bulletin (1986), 34(5), 1907-16.
Liotta et al., Nature, Aug. 26, 2004; 430(7003), pp. 973-974.
Jaboin et al., Cancer Lett. Apr. 10, 2003;193(1), pp. 109-114.
Ashman, L., Int J Biochem Cell Biol. (1999);31(10), pp. 1037-1051.
Sattler et al., Leuk Res. (2004), 28 Suppl 1, pp. S11-20.
Advani, A., Curr Hematol Rep. (2005), 4(1), pp. 51-58.
McKenna, Hilary J. et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. Jun. 2000; 95(11), pp. 3489-3497.
Drexler, H. G. and H. Quentmeier (2004), “FLT3: receptor and ligand”, Growth Factors, 22(2), pp. 71-73.
Stirewalt, D. L. and J. P. Radich,(2003), “The role of FLT3 in haematopoietic malignancies”, Nat Rev Cancer, 3(9): 650-65.
Scheijen, B. and J. D. Griffin, (2002), “Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease”, Oncogene, 21(21), pp. 3314-3333.
Kottaridis, P. D., R. E. Gale, et al. (2003), “Flt3 mutations and leukaemia”, Br J Haematol, 122(4), pp. 523-538.
Ansari Lari, Ali et al., FLT3 mutations in myeloid sarcoma, British Journal of Haematology. (Sep. 2004) 126(6), pp. 785-791.
Gilliliand et al., Blood, (2002), vol. 100, pp. 1532-1542.
Levis, M., K. F. Tse, et al., 2001, “A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.” Blood, 98(3), pp. 885-887.
Tse KF, et al. Inhibition of FLT3 mediated transformation by use of a tyrosine kinase inhibitor. Leukemia. Jul. 2001; 15(7), pp. 1001-1010.
Smith, B. Douglas et al., Single agent CEP 701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia, Blood, May 2004; 103(10), pp. 3669-3676.
Griswold, Ian J. et al. Effects of MLN518, A Dual FLT3 and KIT Inhibitor, on Normal and Malignant Hematopoiesis. Blood, Jul. 2004, 104: 2912-2918.
Yee, Kevin W. H. et al., SU5416 and SU5614 inhibit kinase activity of wild type and mutant FLT3 receptor tyrosine kinase, Blood, Sep. 2002; 100(8), pp. 2941-2949.
O'Farrell, Anne Marie et al., SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo, Blood, May 2003; 101(9), pp. 3597-3605.
Stone, R.M. et al., PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial, Ann Hematol. (2004); 83 Suppl 1, pp. S89-90.
Murata, K. et al., Selective cytotoxic mechanism of GTP 14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms like tyrosine kinase 3 (FLT3), J Biol Chem. Aug. 29, 2003; 278(35), pp. 32892-32898.
Levis, Mark et al., Novel FLT3 tyrosine kinase inhibitors, Expert Opin. Investing. Drugs (2003) 12(12), pp. 1951-1962.
Levis, Mark et al., Small Molecule FLT3 Tyrosine Kinase Inhibitors, Current Pharmaceutical Design, (2004), 10, pp. 1183-1193.
Gould, P., International J. Pharm. (1986), 33, pp. 201-217.
Berge et al., J. Pharm. Sci., Jan. 1977, 66(1), pp. 1-19.
Boothroyd et al., Tet Lett (1995), 36(14), pp. 2411-2414.
Sitzmann et al., J. Org Chem, 1985 , 50, pp. 5879-5881.
Tyrrell et al., Synthesis, (2004), 4, pp. 469-483.
Kristensen et al., Organic Letters, (2001), 3(10), pp. 1435-1437.
Stevenson et al., J. Org. Chem., (1986), 51, pp. 616-620.
Hall et al., Inorganic Chemistry (1997), 36(14), pp. 3096-3101.
Bertani et al., Organometallics, (1996), 15(4), pp. 1236-1241.
Quentmeier H, Reinhardt J, Zaborski M, Drexler HG, FLT3 mutations in acute myeloid leukemia cell lines, Leukemia, (2003),17, pp. 120-124.
Sadick, MD et al., Analysis of Heregulin-Induced ErbB2 Phosphorylation with a High-Throughput Kinase Receptor Activation Enzyme-Linked Immunsorbent Assay, Analytical Biochemistry, (1996), 235, pp. 207-214.
Baumann CA et al., Development of a quantitative, high-throughput cell-based enzyme-linked immunosorbent assay for detection of colony-stimulating factor-1 receptor tyrosine kinase inhibitors, J Biochem Biophys Methods, (2004), 60, pp. 69-79.
Libby P, “Vascular biology of atherosclerosis: overview and state of the art”, Am J Cardiol (2003), 91(3A), pp. 3A-6A.
Helisch A, Schaper W., Arteriogenesis: the development and growth of collateral arteries. Microcirculation, (2003),10(1), pp. 83-97.
Holz FG et al.,“Pathogenesis of lesions in late age-related macular disease”, Am J Ophthalmol. (2004), 137(3), pp. 504-510.
Schiele TM et. Al.,“Vascular restenosis—striving for therapy.” Exper

Affiliated with

Also associated with

Rating

Alkylquinoline and alkylquinazoline kinase modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alkylquinoline and alkylquinazoline kinase modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alkylquinoline and alkylquinazoline kinase modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4261633